| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 08/05/2003 | US6603031 Vitamin D derivatives with cyclic substructures in the side chains, process and intermediate products for their production, and the use for the production of pharmaceutical agents |
| 08/05/2003 | US6603008 Sulfamoylheleroaryl pyrazole compounds as anti-inflammatory/analgesic agents |
| 08/05/2003 | US6602984 Human elastase IV |
| 08/05/2003 | US6602914 Treatment of a disease that is mediated by the expression or suppression of a redox sensitive gene, for example MCP-1, IL-6 and thrombin receptor; antiinflammatory agents; cardio-vascular disorders; atherosclerosis; immunology |
| 08/05/2003 | US6602898 Tricyclic fused heterocycle compounds, process for preparing the same and use thereof |
| 08/05/2003 | US6602890 N-(3,5-dichloropyridin-4-yl)-2-(1-(4-fluorobenzyl)-5 -hydroxyindol-3-yl)-2-oxoacetamide, for example; treating eosinophil-related conditions, including chronic obstructive pulmonary disease |
| 08/05/2003 | US6602881 Anti-inflammatory uses of manzamines |
| 08/05/2003 | US6602878 Acylquanidine derivatives, method for preparing same, application as medicines and pharmaceutical compositions containing them |
| 08/05/2003 | US6602872 Substituted pyridazines having cytokine inhibitory activity |
| 08/05/2003 | US6602707 Mammalian cell surface DNA receptor-encoding nucleic acid |
| 08/05/2003 | US6602667 Of given sequence; useful for diagnosis, prognosis, treatment of inflammatory disorders; screening to identify ligands which bind the polynucleotides |
| 08/05/2003 | US6602519 Peptide factor used as replacement to steroid therapy; neutrophil migration stimulating activity; treating conditions associated with an inflammatory response of septic shock |
| 08/05/2003 | US6602503 Complementarity determining regions (CDRs); asthma and inflammatory bowel disease; integrins; antigen binding regions derived from the heavy and/ or light chain variable regions |
| 08/05/2003 | US6602296 Chemical supplementation of bone |
| 08/05/2003 | US6602274 Targeted transcutaneous cancer therapy |
| 08/05/2003 | CA2079374C (bicyclic-azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis |
| 07/31/2003 | WO2003062414A2 Methods of obtaining isoform specific expression in mammalian cells |
| 07/31/2003 | WO2003062392A2 Methods of treating conditions associated with an edg receptor |
| 07/31/2003 | WO2003062370A2 Multimeric proteins and methods of making and using same |
| 07/31/2003 | WO2003062279A1 Nutraceuticals for the treatment, protection and restoration of connective tissues |
| 07/31/2003 | WO2003062278A1 MONOCLONAL ANTIBODIES AGAINST EXTRACELLULAR LOOPS OF C5aR |
| 07/31/2003 | WO2003062276A2 Multimers of receptor-binding ligands |
| 07/31/2003 | WO2003062275A1 Glycoisoforms of adiponectin and uses thereof |
| 07/31/2003 | WO2003062274A1 Novel proteins and dnas thereof |
| 07/31/2003 | WO2003062271A1 Peptides and nucleic acids of the cathelicidin family, derived from fish, and uses thereof |
| 07/31/2003 | WO2003062252A1 Edg receptor agonists |
| 07/31/2003 | WO2003062248A2 N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists |
| 07/31/2003 | WO2003062245A1 Fused bicyclic pyrimidine derivatives |
| 07/31/2003 | WO2003062241A1 Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function |
| 07/31/2003 | WO2003062240A1 Pteridine derivatives, method for the production thereof, and use thereof |
| 07/31/2003 | WO2003062236A1 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES |
| 07/31/2003 | WO2003062234A1 Quinoxaline compounds |
| 07/31/2003 | WO2003062209A2 Substituted quinazolin-4-ylamine analogues as modulators of capsaicin |
| 07/31/2003 | WO2003062191A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 07/31/2003 | WO2003062189A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 07/31/2003 | WO2003061765A1 Method of prophylaxis against large myocardial infarctions |
| 07/31/2003 | WO2003061688A1 Novel analgesics |
| 07/31/2003 | WO2003061667A1 Pharmaceutically acceptable phosphate-glycerol carrying bodies |
| 07/31/2003 | WO2003061666A1 Phospholipid bodies and use thereof in the treatment of inflammatory and autoimmune diseases |
| 07/31/2003 | WO2003061659A1 Treating stress response with chemokine receptor ccr5 modulators |
| 07/31/2003 | WO2003061655A1 2-aminothiazole allosteric enhancers of a1 adenosine receptors |
| 07/31/2003 | WO2003061653A1 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases |
| 07/31/2003 | WO2003061652A1 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors |
| 07/31/2003 | WO2003061651A1 Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
| 07/31/2003 | WO2003061648A1 Use of cholinesterase antagonists to treat insulin resistance |
| 07/31/2003 | WO2003061645A1 Pharmaceutical use of cox-2 inhibitors in angiogenesis-mediated ocular disorders |
| 07/31/2003 | WO2003061626A1 Polymeric gel system for the controlled delivery of codrugs |
| 07/31/2003 | WO2003061623A1 Solid orally-dispersible pharmaceutical formulation |
| 07/31/2003 | WO2003061620A2 Peptide-carrying bodies for immune response |
| 07/31/2003 | WO2003061365A2 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof |
| 07/31/2003 | WO2003047516A3 Pyrimidine compounds |
| 07/31/2003 | WO2003041649A3 Cyanoalkylamino derivatives as protease inhibitors |
| 07/31/2003 | WO2003040339A3 Antisense modulation of purinoreceptor p2x¿3? |
| 07/31/2003 | WO2003039460A3 Mitotic kinesin inhibitors |
| 07/31/2003 | WO2003035679A3 Molecules |
| 07/31/2003 | WO2003035668A3 Novel anti-inflammatory androstane derivatives -17-carboxy-lactone substituted steroids with an aryl-carboxylic ester in position 17.alpha |
| 07/31/2003 | WO2003028696A3 Compositions for delivery of drug combinations |
| 07/31/2003 | WO2003020702A9 Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain |
| 07/31/2003 | WO2003006016A3 Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury |
| 07/31/2003 | WO2002100408A3 Treating neuropathic/inflammatory pain by targeting a composition (e.g. zd7288) to hcn pacemaker channels |
| 07/31/2003 | WO2002094202B1 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
| 07/31/2003 | WO2002092065A3 Novel methods for the treatment and prevention of pain using stress-activated protein kinase inhibitors |
| 07/31/2003 | WO2002068421A3 Tricyclic compounds and their analogs as inhibitors of cytokine signaling |
| 07/31/2003 | WO2002060875A8 Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes |
| 07/31/2003 | WO2002060464A3 Compositions containing an active fraction isolated from hedyotis diffusae and methods of use |
| 07/31/2003 | WO2002058716A3 Treatment of inflammatory bowel disease using growth factors |
| 07/31/2003 | WO2002030863A3 Ether compounds and compositions for cholesterol management and related uses |
| 07/31/2003 | WO2002024909A3 Receptor nucleic acids and polypeptides |
| 07/31/2003 | WO2002018361A3 Compounds having activity as inhibitors of cytochrome p450rai |
| 07/31/2003 | WO2002012286A3 Stress proteins and peptides and methods of use thereof |
| 07/31/2003 | WO2001034566A3 Protease inhibitors |
| 07/31/2003 | US20030144529 Treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula I Mitogen-activated protein kinases (MAP) is a family of proline- directed serine/threonine kinases that activate their |
| 07/31/2003 | US20030144510 Preparation of pharmaceutical salts |
| 07/31/2003 | US20030144507 Sulfonamide-containing heterocyclic compounds |
| 07/31/2003 | US20030144474 T cell receptor and a biologically active polypeptide with different recognition biding sites connected by a peptide linker; designed to redirect the immune system against various diseases |
| 07/31/2003 | US20030144339 Treatment of inflammatory disease, arthritis, asthma |
| 07/31/2003 | US20030144337 Pyrazole-derived kinase inhibitors and uses thereof |
| 07/31/2003 | US20030144334 Cyclopentabenzofuran derivatives and their use |
| 07/31/2003 | US20030144332 Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals |
| 07/31/2003 | US20030144331 p53 inhibitors and therapeutic use of the same |
| 07/31/2003 | US20030144328 Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 07/31/2003 | US20030144326 Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| 07/31/2003 | US20030144309 Inhibitors of Src and other protein kinases |
| 07/31/2003 | US20030144303 Aminopyrimidine and aminopyridine anti-inflammation agents |
| 07/31/2003 | US20030144302 Process for making substituted pyrazoles |
| 07/31/2003 | US20030144300 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes |
| 07/31/2003 | US20030144298 Therapeutic combinations of antihypertensive and antiangiogenics agents |
| 07/31/2003 | US20030144293 N-alkyl-adamantyl triazinyl benzamide derivatives |
| 07/31/2003 | US20030144292 Protease inhibitors such as N-((4'-Methoxy-(1,1'-biphenyl)-4-yl)-sulfonyl-N-methyl-amino)-(4 -hydroxycyclohexan-1-yl)-acetic acid for prophylaxis of neurodegenerative diseases, vision defects, skin disorders or as antiinflammatory agents |
| 07/31/2003 | US20030144291 Substituted indan derivatives |
| 07/31/2003 | US20030144288 Sulfur compounds such as 4-fluoro-N-(4-methoxy-7-(tetrahydro-pyran-4-yl)-benzothiazol-2-yl) -benzamide, used as preferential adenosine receptor ligands for the prophylaxis of neurodegenerative disorders |
| 07/31/2003 | US20030144286 Nitrogen compounds such as 3-nitro-N-(1H-benzoimidazol-2-yl)-benzamide, used as nonsteroidal antiinflammatory agents, immunology or interleukin receptor associated kinase (IRAK) modulators; rheumatic diseases; multiple sclerosis |
| 07/31/2003 | US20030144284 Heterocyclic imines such as 2-anilino-6-quinoxalinol, used to suppress cell proliferation, differentiation, chemotaxis and/or activation; prophylaxis of restinosis; anticarcinogenic agents |
| 07/31/2003 | US20030144282 Inhibitors of cytosolic phospholipase A2 |
| 07/31/2003 | US20030144281 Substituted benzimidazole compounds |
| 07/31/2003 | US20030144280 Heterocyclic imines, used as cyclooxygenase inhibitors, administered as inflammatory and pain relievers in disorders such as arthritis, neurodegeneration or cancer in mammals |
| 07/31/2003 | US20030144279 5-Heterocyclo-pyrazoles |
| 07/31/2003 | US20030144276 Heterocycle-containing carboxylic acid derivative and drug containing the same |
| 07/31/2003 | US20030144275 Decyclization of oxabenzonorbornadienes or azabicyclic compounds in the presence of catalysts to form naphthalenes, such as 2-methoxy-1,2-dihydronaphthalen-1-ol, used as analgesics, anticarcinogens or viricides; catalysis |
| 07/31/2003 | US20030144274 Preferential enzyme inhibitors such as 3-(4-Methoxyphenyl)-prop-1-ynyl)-N-(4-carboxybenzyl)benzamide, used for prophylaxis of degenerative diseases including cancer and arthritis |